In this trial we hypothesize that abnormal endothelial cilia in adult polycystic Kidney Disease (PKD) patients would have abnormal Nitric Oxide (NO) biosynthesis. Consequently, the trial objectives are the stimulation of ciliary dopamine receptor with dopaminergic agent (Levodopa) in PKD patients to: 1) restore NO biosynthesis and 2) correct their blood pressure.
Inclusion criteria: adult type polycystic kidney disease with borderline hypertension; Control group inclusion criteria are essential borderline hypertension (HTN) without any secondary cause and are age-matched with PKD group.
Exclusion criteria are: Pregnancy, lactation, diabetes mellitus, myocardial infarction, angina, arrhythmias, renal transplantation, renal failure, serum creatinin more than 3mg/dL, dialysis, sever hypertension, recieving antihypertensive drugs.
Study population: Adult Polycystic Kidney Disease (PKD)
Sample size: 30 patients
The intervention drug is levodopa (as the metabolic precursor of dopamine) to stimulate ciliary dopamine receptor.
Main outcome measures are serum nitric oxide and blood pressure.